看到一堆智障高潮，難怪台灣生醫做不起來
請問高端聯亞若沒有要在美國上市，幹嘛去拿美國FDA認證EUA？
台灣是美國第51洲膩？
此外，美國疫苗數量已經夠了，當然沒有發EUA的理由
但其他國家還是水深火熱，疫苗難求好嗎
※ 引述《yu0417 (謙)》之銘言：
: 美國FDA宣布除了最後一支Novavax 疫苗可以採用緊急授權機制外，
: 以後將不再發布EUA任何一家疫苗，美國 FDA 可能不會在大流行期間
: 審查新的 COVID-19 疫苗對 EUA 請求。
: 這是不是意味高端聯亞在取得美國FDA 認證EUA上將面臨新的變數。
: 網址https://reurl.cc/EnRexR
: The U.S. Food and Drug Administration said on Tuesday it may decline to
: review and process new emergency use authorization (EUA) requests for
: COVID-19 vaccines for the rest of the pandemic, if a company has not already
: begun discussions.
: So far, vaccines from Pfizer Inc (PFE.N), Moderna Inc (MRNA.O) and Johnson &
: Johnson (JNJ.N) have been authorized for emergency use in the United States.
: (https://bit.ly/3fOpP2S)
: Novavax Inc (NVAX.O) has had discussions with regulators and said it does not
: expect to seek regulatory authorization for its COVID-19 shot in the United
: States, Britain and Europe until the third quarter of 2021. read more
: Canadian drug developer Medicago said it was in discussions with the FDA for
: an EUA for its plant-based COVID-19 vaccine candidate, which is enhanced by a
: GlaxoSmithKline (GSK.L) treatment.
: AstraZeneca (AZN.L) also has discussed plans for its COVID-19 vaccine with
: U.S. officials. However, the Wall Street Journal earlier this month reported
: that it was considering skipping U.S. emergency-use authorization and instead
: pursue the more time-intensive application for a full-fledged license to sell
: the shot. read more
: AstraZeneca and Novavax did not immediately respond to requests for comment.
: Our Standards: The Thomson Reuters Trust Principles.
: 這是真的嗎?